<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00417716</url>
  </required_header>
  <id_info>
    <org_study_id>APEC-0011</org_study_id>
    <nct_id>NCT00417716</nct_id>
  </id_info>
  <brief_title>Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema</brief_title>
  <official_title>The Efficacy of a Single Intravitreal Injection of Bevacizumab in Patients With Diffuse Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociación para Evitar la Ceguera en México</source>
  <brief_summary>
    <textblock>
      Intravitreal Bevacizumab is an effective treatment for the diffuse diabetic macular edema
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A non-randomized prospective clinical interventional study which includes 45 non previously
      treated patients with DME. The patients received a single intravitreal injection of 2.5 mg
      bevacizumab. Follow-up included clinical examination (best corrected visual acuity (BCVA,
      intraocular pressure (IOP), cataract grading, DME characteristics and systemic check-up)
      pre-injection, at first visit, at weeks 1 and 2 and months 1 and 3. OCT and fluorescein
      angiography was evaluated at months 1 and 3.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <completion_date>May 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BCVA</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Fluorescein Angiography</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Optical Coherence Tomography</measure>
  </primary_outcome>
  <enrollment>45</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <condition>Diabetic Macular Edema</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Bevacizumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  Macular edema involving the center of the macula demonstrated on OCT

          -  Clear ocular media

          -  Untreated patients

          -  Older than 45 years

          -  BCVA of the fellow eye at least 20/100

        Exclusion Criteria:

          -  Renal diabetic disease, uncontrolled hypertension or stroke history

          -  Other ocular disease

          -  Ocular surgery excepting uncomplicated phacoemulsification

          -  History of photocoagulation (panretinal or focal)

          -  History of another intravitreal treatment (like triamcinolone)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriana Solís-Vivanco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asociación para Evitar la Ceguera en México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jans Fromow-Guerra, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Asociación para Evitar la Ceguera en México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Reyna-Castelán</last_name>
    <role>Study Chair</role>
    <affiliation>Asociación para Evitar la Ceguera en México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan M Jiménez-Sierra, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Asociación para Evitar la Ceguera en México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myriam Hernández-Rojas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Asociación para Evitar la Ceguera en México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Griselda Alvarez-Rivera, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Asociación para Evitar la Ceguera en México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hugo Quiroz-Mercado, MD</last_name>
    <role>Study Director</role>
    <affiliation>Asociación para Evitar la Ceguera en México</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asociación para Evitar la Ceguera en México</name>
      <address>
        <city>Mexico city</city>
        <state>Distrito Federal</state>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>June 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2006</study_first_submitted>
  <study_first_submitted_qc>January 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2007</study_first_posted>
  <last_update_submitted>January 3, 2007</last_update_submitted>
  <last_update_submitted_qc>January 3, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2007</last_update_posted>
  <keyword>Diffuse Diabetic Macular Edema</keyword>
  <keyword>Intravitreal Bevacizumab</keyword>
  <keyword>Anti-VEGF drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

